Rudimentary analysis, but thanks for taking the time to post, Davisite.
I think you have underplayed the sheer size of the colorectal market and the scope for opportunities in this space.
While it may be true that the competitive landscape for blood-based screening of colorectal cancer is heating up, it is important to analyse the differences, strengths and weaknesses of each individual test. Of course, one must assume that there will be multiple tests available in the future, but I don't think a range of options will dilute RHY's impact - given the size of the market and the inability of other tests to provide mass screening.
Viollier's Epigenomics test is a molecular/DNA test vs RHY's antibody test. You mentioned that you have worked in the molecular biology field for quite some time. You would then know full well that a molecular/DNA test is a significantly more expensive test that requires hospitals/labs to have special infrastructure (machines) to perform the test vs a simple mass screening blood test which uses existing infrastructure. A much easier sell for RHY vs the existing options for mine.
RHY recently (and successfully) developed the reagents - the antibodies/antigen of the testing kit. Study 6 (to be completed next year) will provide further verification & Study 7 (Clinical Trial) is another major milestone to be checked off in 2019. RHY will then shift their focus to regulatory approval and commercial opps later in the year. I believe they are well-funded to complete Study 7, so any suggestion of a looming CR is disingenuous.
And I will be increasing my investment in RHY in the coming months.
